424 related articles for article (PubMed ID: 32964312)
1. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.
Kakeji Y; Oshikiri T; Takiguchi G; Kanaji S; Matsuda T; Nakamura T; Suzuki S
Esophagus; 2021 Jan; 18(1):25-32. PubMed ID: 32964312
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
Fick CN; Dunne EG; Sihag S; Molena D; Cytryn SL; Janjigian YY; Wu AJ; Worrell SG; Hofstetter WL; Jones DR; Gray KD
Ann Thorac Surg; 2024 Jul; 118(1):130-140. PubMed ID: 38408631
[TBL] [Abstract][Full Text] [Related]
3. The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma.
Hirano H; Boku N
Asia Pac J Clin Oncol; 2018 Aug; 14(4):291-299. PubMed ID: 29873183
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q; Liu T; Ding Z
Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
[TBL] [Abstract][Full Text] [Related]
5. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
6. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
7. Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy.
Yan Y; Feng X; Li C; Lerut T; Li H
Chin Med J (Engl); 2022 Sep; 135(18):2143-2156. PubMed ID: 36525602
[TBL] [Abstract][Full Text] [Related]
8. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
van der Woude SO; Hulshof MC; van Laarhoven HW
Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
[TBL] [Abstract][Full Text] [Related]
9. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
[TBL] [Abstract][Full Text] [Related]
11. Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.
Tsuji T; Matsuda S; Takeuchi M; Kawakubo H; Kitagawa Y
Jpn J Clin Oncol; 2023 Jul; 53(8):645-652. PubMed ID: 37282626
[TBL] [Abstract][Full Text] [Related]
12. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
[TBL] [Abstract][Full Text] [Related]
13. [Hotspots and prospects of esophageal cancer research in China].
Mao YS; Gao SG; Li Y; Xue Q; Li F; Jin DH; Yi H; He J
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):307-311. PubMed ID: 37072305
[TBL] [Abstract][Full Text] [Related]
14. Perioperative therapy for esophageal cancer.
Yamasaki M; Miyata H; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Gen Thorac Cardiovasc Surg; 2014 Sep; 62(9):531-40. PubMed ID: 25065567
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatments for resectable carcinoma of the esophagus.
Leowattana W; Leowattana P; Leowattana T
World J Gastroenterol; 2023 Aug; 29(30):4628-4641. PubMed ID: 37662861
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
[TBL] [Abstract][Full Text] [Related]
18. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
Fu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
[TBL] [Abstract][Full Text] [Related]
19. Preoperative therapy in locally advanced esophageal cancer.
Garg PK; Sharma J; Jakhetiya A; Goel A; Gaur MK
World J Gastroenterol; 2016 Oct; 22(39):8750-8759. PubMed ID: 27818590
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Xu Y; Yu X; Chen Q; Mao W
World J Surg Oncol; 2012 Aug; 10():173. PubMed ID: 22920951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
